培菲康联合美沙拉嗪对轻、中度活动期溃疡性结肠炎患者的临床疗效和安全性研究

Study on the clinical efficacy and safety of bifico combined with mesalazine in patients with mild to moderate active ulcerative colitis

目的探讨轻、中度活动期溃疡性结肠炎患者应用培菲康与美沙拉嗪联合治疗的临床价值,并分析其用药安全性。方法将我院在2017年9月~2018年5月收治的78例轻、中度活动期溃疡性结肠炎患者作为本次研究病例,按照治疗手段的不同对患者进行分组,研究组与对照组各39例,对照组单纯应用美沙拉嗪治疗,研究组采取培菲康与美沙拉嗪联合治疗,比较两组的临床效果。结果治疗后,研究组TNF-α(31.60±14.50)、IL-23(513.20±60.80)、IL-17(221.50±51.60)的检测水平以及治疗总有效率与对照组比较差异明显,具有统计学意义。结论将培菲康与美沙拉嗪联合应用在轻、中度活动期溃疡性结肠炎患者的治疗中,效果明显,价值显著,不仅能够提高患者的治疗总有效率,还能够改善患者体内的炎症细胞因子水平,对延缓患者病症发展有积极促进的作用,临床价值较高,值得临床探索。

Objective To investigate the clinical value of the combination of bifico and mesalazine in patients with mild to moderate active ulcerative colitis, and to analyze the safety of the drug. Methods 78 patients with mild to moderate active ulcerative colitis admitted in our hospital from September 2017 to May 2018 were enrolled in this study. Patients were grouped according to different treatment methods, including study group(n=39) and control group(n=39). The control group was treated with mesalazine alone. The study group was treated with bifico and mesalazine. The clinical effects of the two groups were compared. Results After treatment, there were significant differences in the detection levels of TNF-α(31.60±14.50), IL-23 (513.20±60.80) and IL-17 (221.50±51.60) and the total effective rate of treatment between the study group and the control group, which were statistically significant. Conclusion The combination of bifico and mesalazine in the treatment of patients with mild to moderate active ulcerative colitis has obvious effects and significant value. It can not only improve the total effective rate of patients, but also improve the level of inflammatory cytokines in the body of patients. It plays a positive role in delaying the development of patients' diseases, and its clinical value is high, which is worthy of clinical exploration.